| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1379601 | Bioorganic & Medicinal Chemistry Letters | 2005 | 4 Pages |
Abstract
Modulation of the metabotropic glutamate subtype 5 (mGlu5) receptor may be useful in the treatment of a variety of central nervous system disorders. Herein, we report on the discovery, synthesis, and biological evaluation of dipyridyl amines as small molecule mGlu5 antagonists.
Graphical abstractThe metabotropic glutamate subtype 5 (mGlu5) receptor has been implicated in a number of CNS disorders. Herein, we report on the discovery, synthesis, and biological evaluation of dipyridyl amines as small molecule mGlu5 antagonists.Figure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Theodore M. Kamenecka, Céline Bonnefous, Steven Govek, Jean-Michel Vernier, John Hutchinson, Janice Chung, Grace Reyes-Manalo, Jeffery J. Anderson,